Toro Research Initiates Coverage of Sunwin International Neutraceuticals

Miramar, FLA October 26, 2009/Value Press Wire/ – Toro Research is initiating coverage of Sunwin International Neutraceuticals Inc. (OTCBB: SUWN), a diversified nutraceutical company, with a speculative “Buy” recommendation and a performance rating of 8.5, on a scale of 10.

To view the complete report, please visist:
http://www.tororesearch.com/reports/SUWN/SUWN_102609.pdf

The report states: "The recommendation is based on several considerations, such as the company's past financial performance, which included annual net revenues in upwards of Twenty Million dollars for the fiscal year ended April 30, 2009, as well as a well-established operating history."

"But of particular interest are the recent developments in one of the company's key markets, which included the December 2008 FDA approval of Reb A, an active ingredient found in one of Sunwin International's products, stevia. As an established and leading producer of stevia for years now, Toro Research believes the company is uniquely positioned to meet the surging global demand that is just beginning to scratch the surface of the billion dollar “Artificial Sweetener” industry. Consequently, it is important to note, Sunwin International has recently attained FDA self-affirmed GRAS status, clearing the way for the company’s high grade extracts to be used in food and beverage."

Content Disclaimer:

Readers are urged to carefully read the disclaimer found at the end of the Toro Research report. Toro Research is not a registered securities broker/dealer, investment advisor or financial analyst. The materials contained in the Toro Research report are offered for informational purposes only, and should be viewed as commercial advertisement. The report is not intended to be investment advice. The report may contain inaccuracies and errors. Sunwin International Neutraceuticals does not warrant the accuracy or completeness of the materials or the reliability of any advice, opinion, statement or other information in the Toro Research report. Any reliance on any such opinion, advice, statement, memorandum, or information shall be at your sole risk.

Toro Research has been compensated $3,000 by third party Stock Market Alert LLC., (who is under contract and has been compensated by a third party to perform an investor relations campaign for SUWN) for the creation of this report. All direct and third party compensation received has been disclosed within each individual profile in accordance with section 17(b) of the Securities Act of 1933. Toro research certifies that it currently does not own, nor will it own any securities or securities of the company profiled in this report

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Toro Research undertakes no obligation to update such statements.